Lantern Pharma rises on FDA 'fast track' tag for breast cancer drug

Lantern Pharma

03/12/2024 13:43

** Shares of cancer drug developer Lantern Pharma  LTRN.O 
rise ~15% to $3.63 premarket
    ** LTRN says the U.S. Food and Drug Administration has
granted "fast track" designation to its experimental drug to
treat a type of breast cancer called triple negative breast
cancer (TNBC)
    ** The drug, LP-184, showed preclinical efficacy in treating
TNBC - LTRN 
    ** FDA's "fast track" status expedites the review of
medicines to treat serious conditions
    ** As of last close, stock has fallen 26.2% YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))